458 related articles for article (PubMed ID: 31871236)
1. Influenza Hemagglutinin Structures and Antibody Recognition.
Wu NC; Wilson IA
Cold Spring Harb Perspect Med; 2020 Aug; 10(8):. PubMed ID: 31871236
[TBL] [Abstract][Full Text] [Related]
2. Mapping of a Novel H3-Specific Broadly Neutralizing Monoclonal Antibody Targeting the Hemagglutinin Globular Head Isolated from an Elite Influenza Virus-Immunized Donor Exhibiting Serological Breadth.
Qiu Y; Stegalkina S; Zhang J; Boudanova E; Park A; Zhou Y; Prabakaran P; Pougatcheva S; Ustyugova IV; Vogel TU; Mundle ST; Oomen R; Delagrave S; Ross TM; Kleanthous H; Qiu H
J Virol; 2020 Feb; 94(6):. PubMed ID: 31826999
[TBL] [Abstract][Full Text] [Related]
3. Conformational Stability of the Hemagglutinin of H5N1 Influenza A Viruses Influences Susceptibility to Broadly Neutralizing Stem Antibodies.
Wang W; Song HS; Keller PW; Alvarado-Facundo E; Vassell R; Weiss CD
J Virol; 2018 Jun; 92(12):. PubMed ID: 29593038
[TBL] [Abstract][Full Text] [Related]
4. A Perspective on the Structural and Functional Constraints for Immune Evasion: Insights from Influenza Virus.
Wu NC; Wilson IA
J Mol Biol; 2017 Aug; 429(17):2694-2709. PubMed ID: 28648617
[TBL] [Abstract][Full Text] [Related]
5. Potential Role of Nonneutralizing IgA Antibodies in Cross-Protective Immunity against Influenza A Viruses of Multiple Hemagglutinin Subtypes.
Okuya K; Yoshida R; Manzoor R; Saito S; Suzuki T; Sasaki M; Saito T; Kida Y; Mori-Kajihara A; Kondoh T; Sato M; Kajihara M; Miyamoto H; Ichii O; Higashi H; Takada A
J Virol; 2020 Jun; 94(12):. PubMed ID: 32269119
[TBL] [Abstract][Full Text] [Related]
6. Mini-HA Is Superior to Full Length Hemagglutinin Immunization in Inducing Stem-Specific Antibodies and Protection Against Group 1 Influenza Virus Challenges in Mice.
van der Lubbe JEM; Verspuij JWA; Huizingh J; Schmit-Tillemans SPR; Tolboom JTBM; Dekking LEHA; Kwaks T; Brandenburg B; Meijberg W; Zahn RC; Roozendaal R; Kuipers H
Front Immunol; 2018; 9():2350. PubMed ID: 30369928
[TBL] [Abstract][Full Text] [Related]
7. Broadly neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones.
He W; Mullarkey CE; Duty JA; Moran TM; Palese P; Miller MS
J Virol; 2015 Apr; 89(7):3610-8. PubMed ID: 25589655
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin.
Tan GS; Lee PS; Hoffman RM; Mazel-Sanchez B; Krammer F; Leon PE; Ward AB; Wilson IA; Palese P
J Virol; 2014 Dec; 88(23):13580-92. PubMed ID: 25210195
[TBL] [Abstract][Full Text] [Related]
9. Elicitation of broadly neutralizing influenza antibodies in animals with previous influenza exposure.
Wei CJ; Yassine HM; McTamney PM; Gall JG; Whittle JR; Boyington JC; Nabel GJ
Sci Transl Med; 2012 Aug; 4(147):147ra114. PubMed ID: 22896678
[TBL] [Abstract][Full Text] [Related]
10. Novel universal influenza virus vaccine approaches.
Krammer F
Curr Opin Virol; 2016 Apr; 17():95-103. PubMed ID: 26927813
[TBL] [Abstract][Full Text] [Related]
11. Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages.
Corbett KS; Moin SM; Yassine HM; Cagigi A; Kanekiyo M; Boyoglu-Barnum S; Myers SI; Tsybovsky Y; Wheatley AK; Schramm CA; Gillespie RA; Shi W; Wang L; Zhang Y; Andrews SF; Joyce MG; Crank MC; Douek DC; McDermott AB; Mascola JR; Graham BS; Boyington JC
mBio; 2019 Feb; 10(1):. PubMed ID: 30808695
[TBL] [Abstract][Full Text] [Related]
12. Mutations in the Hemagglutinin Stalk Domain Do Not Permit Escape from a Protective, Stalk-Based Vaccine-Induced Immune Response in the Mouse Model.
Roubidoux EK; Carreño JM; McMahon M; Jiang K; van Bakel H; Wilson P; Krammer F
mBio; 2021 Feb; 12(1):. PubMed ID: 33593972
[TBL] [Abstract][Full Text] [Related]
13. Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses.
Allen JD; Jang H; DiNapoli J; Kleanthous H; Ross TM
J Virol; 2019 Feb; 93(3):. PubMed ID: 30429350
[TBL] [Abstract][Full Text] [Related]
14. Broadly neutralizing antibodies against influenza viruses.
Laursen NS; Wilson IA
Antiviral Res; 2013 Jun; 98(3):476-83. PubMed ID: 23583287
[TBL] [Abstract][Full Text] [Related]
15. An Improved Inactivated Influenza Vaccine with Enhanced Cross Protection.
Ni Y; Guo J; Turner D; Tizard I
Front Immunol; 2018; 9():1815. PubMed ID: 30140267
[TBL] [Abstract][Full Text] [Related]
16. Chimeric hemagglutinin vaccine elicits broadly protective CD4 and CD8 T cell responses against multiple influenza strains and subtypes.
Liao HY; Wang SC; Ko YA; Lin KI; Ma C; Cheng TR; Wong CH
Proc Natl Acad Sci U S A; 2020 Jul; 117(30):17757-17763. PubMed ID: 32669430
[TBL] [Abstract][Full Text] [Related]
17. Implications of broadly neutralizing antibodies in the development of a universal influenza vaccine.
Cho A; Wrammert J
Curr Opin Virol; 2016 Apr; 17():110-115. PubMed ID: 27031684
[TBL] [Abstract][Full Text] [Related]
18. A Prevalent Focused Human Antibody Response to the Influenza Virus Hemagglutinin Head Interface.
McCarthy KR; Lee J; Watanabe A; Kuraoka M; Robinson-McCarthy LR; Georgiou G; Kelsoe G; Harrison SC
mBio; 2021 Jun; 12(3):e0114421. PubMed ID: 34060327
[TBL] [Abstract][Full Text] [Related]
19. Computationally Optimized Broadly Reactive H2 HA Influenza Vaccines Elicited Broadly Cross-Reactive Antibodies and Protected Mice from Viral Challenges.
Reneer ZB; Jamieson PJ; Skarlupka AL; Huang Y; Ross TM
J Virol; 2020 Dec; 95(2):. PubMed ID: 33115871
[TBL] [Abstract][Full Text] [Related]
20. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses.
Margine I; Krammer F; Hai R; Heaton NS; Tan GS; Andrews SA; Runstadler JA; Wilson PC; Albrecht RA; García-Sastre A; Palese P
J Virol; 2013 Oct; 87(19):10435-46. PubMed ID: 23903831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
